세계의 혈전 용해제 시장 : 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Thrombolytic Drugs Market was valued at USD 2.9 billion in 2024 and is estimated to grow at a CAGR of 8.1% to reach USD 6.4 billion by 2034. This steady rise reflects the growing burden of cardiovascular diseases across the globe, including heart attacks, strokes, pulmonary embolism, and other clot-related conditions. As sedentary lifestyles, obesity, hypertension, and aging populations become increasingly common, the prevalence of thromboembolic events is accelerating. These trends are driving significant demand for fast-acting clot-dissolving medications that can be administered effectively in emergencies. Health systems are recognizing the urgency of such treatments, especially in acute care settings, where rapid intervention is critical for improving patient outcomes.

Technology is playing a vital role in propelling the market forward. Advancements in drug development and delivery methods are helping enhance the precision and efficiency of thrombolytic therapies. Innovations in dosing and formulation are also supporting broader clinical adoption. Alongside these developments, awareness surrounding early intervention is growing, thanks to improved diagnostic and imaging technologies. Timely detection and prompt treatment are becoming the standard in hospitals and emergency rooms, where these drugs are most commonly used. As clinical practice evolves, so does the need for therapeutics that are not only effective but also safe and easy to administer.

Thrombolytic drugs, often referred to as fibrinolytic agents, are essential in dissolving blood clots that form due to various cardiovascular conditions. These medications work by activating the body's fibrinolytic system to break down fibrin, the primary protein found in clots. The market comprises several key categories, including tissue plasminogen activators (tPAs), streptokinase, and urokinase-type plasminogen activators (uPAs), with applications mostly concentrated in hospitals and critical care settings.

Among these, the tPAs segment led the global market, generating USD 2.3 billion in revenue in 2024. This segment is expected to rise to USD 5.1 billion by 2034, growing at a CAGR of 8.2%. The dominance of tPAs stems from their high efficacy in clot resolution during critical health events. These agents are widely prescribed due to well-documented clinical benefits when used promptly in acute cases. One of the underlying drivers of increased tPA utilization is the global surge in diabetes cases. The disease heightens the risk of thrombotic events through vascular damage, increased clotting tendencies, and metabolic imbalances, all of which raise the need for aggressive clot-busting therapies.

In terms of medical conditions treated with thrombolytics, ischemic stroke represented the largest indication segment, accounting for 31.3% of the global market share in 2024. This segment is on track to maintain strong growth through 2034, supported by the high incidence of ischemic strokes, which make up the majority of stroke cases globally. These strokes are typically caused by obstructions in cerebral blood flow and require immediate medical attention. The growing number of stroke cases worldwide, combined with rising awareness of stroke prevention and management, is increasing the demand for thrombolytic therapies. Conditions such as diabetes, high blood pressure, and obesity-commonly linked to stroke risk-are further boosting the need for effective medical intervention using these drugs.

By end user, hospitals emerged as the leading segment in 2024, holding a 54.8% share of the market. This segment is expected to reach USD 3.4 billion by 2034, progressing at a CAGR of 7.7%. Hospitals serve as the primary point of care for patients requiring thrombolytic treatment, thanks to their ability to conduct rapid diagnostics and initiate therapy without delay. The increasing frequency of emergency admissions due to heart attacks and strokes continues to support hospital demand. Additionally, global investment in critical care infrastructure is expanding access to such treatments, especially in urban areas and developed healthcare systems. While outpatient centers are gaining traction, hospital settings remain the cornerstone of thrombolytic drug administration.

Regionally, North America led the market in 2024, generating USD 2 billion in revenue. The region is forecasted to reach USD 4.3 billion by 2034, growing at a CAGR of 7.9%. The market leadership of North America can be attributed to its advanced healthcare infrastructure, favorable reimbursement environment, and high prevalence of thrombotic disorders. The increased adoption of advanced therapies and supportive healthcare policies in this region continue to drive the demand for thrombolytics. Additionally, pharmaceutical innovation, a robust clinical pipeline, and strong industry presence contribute to the region's dominance in the global landscape.

The competitive environment is defined by leading players investing in research, expanding product lines, and targeting emerging markets to broaden access. Companies are striving to improve drug safety profiles and streamline delivery methods to maintain their edge in a tightly regulated, performance-focused market. These efforts underscore the ongoing evolution of thrombolytic drug development, shaped by innovation, clinical demand, and strategic positioning.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Drug class
  • 2.2.3 Indication
  • 2.2.4 End use
• 2.3 CXO perspectives: strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of cardiovascular and cerebrovascular events
    • 3.2.1.2 Expansion of primary stroke centers and emergency care infrastructure
    • 3.2.1.3 Advancements in thrombolytic drug formulations
    • 3.2.1.4 Favorable guidelines and protocol inclusion
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High risk of bleeding and narrow therapeutic window
    • 3.2.2.2 Competition from mechanical interventions and direct oral anticoagulants (DOACs)
  • 3.2.3 Market opportunities
    • 3.2.3.1 Government initiatives and funding
    • 3.2.3.2 Development of thrombolytics tailored to rare clotting disorders
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Future market trends
• 3.6 Regulatory landscape
  • 3.6.1 North America
  • 3.6.2 Europe
  • 3.6.3 Asia Pacific
• 3.7 Clinical trial analysis
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Key developments
  • 4.5.1 Mergers and acquisitions
  • 4.5.2 Partnerships and collaborations
  • 4.5.3 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Tissue plasminogen activators (tPAs)
• 5.3 Streptokinase derivatives
• 5.4 Urokinase-type plasminogen activators (uPAs)

Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Ischemic stroke
• 6.3 Myocardial infarction
• 6.4 Pulmonary embolism
• 6.5 Deep vein thrombosis
• 6.6 Catheter occlusion
• 6.7 Other indications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Boehringer Ingelheim
• 9.3 Chiesi Farmaceutici
• 9.4 Genentech (F. Hoffmann-La Roche)
• 9.5 Gennova Biopharmaceuticals
• 9.6 Karma Pharmatech
• 9.7 Lupin
• 9.8 MicrobixBiosystems
• 9.9 Reliance Lifesciences
• 9.10 TechpoolBio-Pharma (Shanghai Pharma)